

**Amendments to the Claims:**

Claims 1-30 are pending. Claims 1,5, 15-22 and 26 (all in part), 3, 7, 10, 13, 24, 28 and 30 are withdrawn from consideration. Claims 1, 5, 15-22, and 26 (all in part), 2, 4, 6, 8, 9, 11, 12, 14, 23, 25, 27 and 29 are rejected. Claim 1, 15-21 are amended.

The following listing of claims will replace all prior versions, and listings, of claims in the application.

**Listings of Claims:**

1. (Currently Amended) A method of treating sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a dopamine D<sub>4</sub> receptor agonist or a pharmaceutically acceptable salt thereof with the proviso that said dopamine D<sub>4</sub> receptor agonist is not 5,6,6a,7-tetrahydro-6-methyl-4H-Dibenzo[de,g]quinoline-10,11-diol.

2. (Original) A method of treating male sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a dopamine D<sub>4</sub> receptor agonist or a pharmaceutically acceptable salt thereof with the proviso that said dopamine D<sub>4</sub> receptor agonist is not 5,6,6a,7-tetrahydro-6-methyl-4H-Dibenzo[de,g]quinoline-10,11-diol.

3. (Cancelled)

4. (Original) A method of treating male erectile dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a dopamine D<sub>4</sub> receptor agonist or a pharmaceutically acceptable salt thereof with the proviso that said dopamine D<sub>4</sub> receptor agonist is not 5,6,6a,7-tetrahydro-6-methyl-4H-Dibenzo[de,g]quinoline-10,11-diol.

5. (Original) A method of treating sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D<sub>4</sub> receptor agonist or a pharmaceutically acceptable salt thereof.

6. (Original) A method of treating male sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D<sub>4</sub> receptor agonist or a pharmaceutically acceptable salt thereof.

7. (Cancelled)

8. (Original) A method of treating male erectile dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D<sub>4</sub> receptor agonist or a pharmaceutically acceptable salt thereof.

9. (Original) The method of claim 6 wherein said selective dopamine D<sub>4</sub> receptor agonist is N-([4-(2-cyanophenyl)-1-piperazinyl]methyl)-3-methylbenzamide or a pharmaceutically acceptable salt thereof.

10. (Cancelled)

11. (Original) The method of claim 8 wherein said selective dopamine D<sub>4</sub> receptor agonist is N-([4-(2-cyanophenyl)-1-piperazinyl]methyl)-3-methylbenzamide or a pharmaceutically acceptable salt thereof.

12. (Original) The method of claim 6 wherein said selective dopamine D<sub>4</sub> receptor agonist is 5-fluoro-2-([4-(2-pyridinyl)-1-piperazinyl]methyl)-1H-indole or a pharmaceutically acceptable salt thereof.

13. (Cancelled)

14. (Original) The method of claim 8 wherein said selective dopamine D<sub>4</sub> receptor agonist is 5-fluoro-2-([4-(2-pyridinyl)-1-piperazinyl]methyl)-1H-indole or a pharmaceutically acceptable salt thereof.

15. (Currently Amended) ~~A- The~~ method of claim 5 wherein said selective dopamine D<sub>4</sub> receptor agonist is 25 fold more selective for the D<sub>4</sub> receptor than for the D<sub>2</sub> receptor.

16. (Currently Amended) ~~A- The~~ method of claim 5 wherein said selective dopamine D<sub>4</sub> receptor agonist is 50 fold more selective for the D<sub>4</sub> receptor than for the D<sub>2</sub> receptor.

17. (Currently Amended) ~~A- The~~ method of claim 5 wherein said selective dopamine D<sub>4</sub> receptor agonist is 100 fold more selective for the D<sub>4</sub> receptor than for the D<sub>2</sub> receptor.

18. (Currently Amended) ~~A- The~~ method of claim 5 wherein said selective dopamine D<sub>4</sub> receptor agonist is 200 fold more selective for the D<sub>4</sub> receptor than for the D<sub>2</sub> receptor.

19. (Currently Amended) ~~A- The~~ method of claim 5 wherein said selective dopamine D<sub>4</sub> receptor agonist is 300 fold more selective for the D<sub>4</sub> receptor than for the D<sub>2</sub> receptor.

20. (Currently Amended) ~~A~~The method of claim 5 wherein said selective dopamine D<sub>4</sub> receptor agonist is 500 fold more selective for the D<sub>4</sub> receptor than for the D<sub>2</sub> receptor.

21. (Currently Amended) ~~A~~The method of claim 5 wherein said selective dopamine D<sub>4</sub> receptor agonist is 1000 fold more selective for the D<sub>4</sub> receptor than for the D<sub>2</sub> receptor.

22. (Original) A method of treating sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D<sub>4</sub> receptor agonist or a pharmaceutically acceptable salt thereof wherein said agonist does not cause significant emesis.

23. (Original) A method of treating male sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D<sub>4</sub> receptor agonist or a pharmaceutically acceptable salt thereof thereof wherein said agonist does not cause significant emesis.

24. (Cancelled)

25. (Original) A method of treating male erectile dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D<sub>4</sub> receptor agonist or a pharmaceutically acceptable salt thereof thereof wherein said agonist does not cause significant emesis.

26. (Original) A method of treating sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D<sub>4</sub> receptor agonist or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier.

27. (Original) A method of treating male sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D<sub>4</sub> receptor agonist or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier.

28. (Cancelled)

29. (Original) A method of treating male erectile dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D<sub>4</sub> receptor agonist or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier.

30. (Cancelled)